L Kuksa1, V Riekstina2, V Leimane2, I Ozere1, G Skenders2, R Van den Bergh3, K Kremer4, C D Acosta4, A D Harries5. 1. Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia ; Riga Stradins University, Riga, Latvia. 2. Riga East University Hospital TB and Lung Disease Centre, Riga, Latvia. 3. Medical Department, Operational Center Brussels, Médecins Sans Frontières, MSF-Luxembourg, Luxembourg. 4. Tuberculosis and M/XDR-TB Programme, Division of Communicable Diseases, Health Security & Environment, World Health Organization Regional Office for Europe, Copenhagen, Denmark. 5. International Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK.
Abstract
SETTING: Drug-resistant tuberculosis (TB) is an important public health problem in Latvia. OBJECTIVE: To document trends, characteristics and treatment outcomes of registered patients with multi-drug-resistant (MDR-) and extensively drug-resistant (XDR-) TB in Latvia from 2000 to 2010. DESIGN: A retrospective national cohort study. RESULTS: Of 1779 patients, 1646 (92%) had MDR- and 133 (8%) XDR-TB. Over 11 years, the proportion of XDR-TB among MDR-TB patients increased from 2% to 18%. Compared to MDR-TB patients, those with XDR-TB were significantly more likely to have failed MDR-TB treatment (OR 8.4, 95%CI 4.3-16.2), have human immunodeficiency virus infection (OR 3.2, 95%CI 1.8-5.7), be illegal drug users (OR 5.7, 95%CI 2.6-11.6) or have had contact with MDR-TB patients (OR 1.9, 95%CI 1.3-2.8). Cure rates for XDR-TB were 50%. Compared with MDR-TB patients, those with XDR-TB had a higher risk of treatment failure (29% vs. 8%, respectively, P < 0.001). Unfavourable treatment outcomes were significantly associated with being male; having smear-positive disease; pulmonary cavities; failure, default or relapse after previous MDR-TB treatment; and a history of incarceration. CONCLUSION: More MDR-TB in Latvia is now also XDR-TB. This study identified several risk factors for XDR-TB and, for unfavourable treatment outcomes, highlighting the importance of early diagnosis and appropriate management of MDR-/XDR-TB.
SETTING: Drug-resistant tuberculosis (TB) is an important public health problem in Latvia. OBJECTIVE: To document trends, characteristics and treatment outcomes of registered patients with multi-drug-resistant (MDR-) and extensively drug-resistant (XDR-) TB in Latvia from 2000 to 2010. DESIGN: A retrospective national cohort study. RESULTS: Of 1779 patients, 1646 (92%) had MDR- and 133 (8%) XDR-TB. Over 11 years, the proportion of XDR-TB among MDR-TB patients increased from 2% to 18%. Compared to MDR-TB patients, those with XDR-TB were significantly more likely to have failed MDR-TB treatment (OR 8.4, 95%CI 4.3-16.2), have human immunodeficiency virus infection (OR 3.2, 95%CI 1.8-5.7), be illegal drug users (OR 5.7, 95%CI 2.6-11.6) or have had contact with MDR-TB patients (OR 1.9, 95%CI 1.3-2.8). Cure rates for XDR-TB were 50%. Compared with MDR-TB patients, those with XDR-TB had a higher risk of treatment failure (29% vs. 8%, respectively, P < 0.001). Unfavourable treatment outcomes were significantly associated with being male; having smear-positive disease; pulmonary cavities; failure, default or relapse after previous MDR-TB treatment; and a history of incarceration. CONCLUSION: More MDR-TB in Latvia is now also XDR-TB. This study identified several risk factors for XDR-TB and, for unfavourable treatment outcomes, highlighting the importance of early diagnosis and appropriate management of MDR-/XDR-TB.
Entities:
Keywords:
Europe; Latvia; SORT IT; XDR-TB; operational research
Authors: Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder Journal: Am J Respir Crit Care Med Date: 2010-05-04 Impact factor: 21.405
Authors: M Edginton; D Enarson; R Zachariah; T Reid; S Satyanarayana; K Bissell; S G Hinderaker; T Harries Journal: Public Health Action Date: 2012-03-21
Authors: Salmaan Keshavjee; Irina Y Gelmanova; Paul E Farmer; Sergey P Mishustin; Aivar K Strelis; Yevgeny G Andreev; Alexander D Pasechnikov; Sidney Atwood; Joia S Mukherjee; Michael L Rich; Jennifer J Furin; Edward A Nardell; Jim Y Kim; Sonya S Shin Journal: Lancet Date: 2008-08-22 Impact factor: 79.321
Authors: V Leimane; G Dravniece; V Riekstina; I Sture; S Kammerer; M P Chen; G Skenders; T H Holtz Journal: Eur Respir J Date: 2010-02-25 Impact factor: 16.671
Authors: A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley Journal: Antimicrob Agents Chemother Date: 2012-03-05 Impact factor: 5.191
Authors: A C Miller; I Y Gelmanova; S Keshavjee; S Atwood; G Yanova; S Mishustin; J J Furin; S S Shin Journal: Int J Tuberc Lung Dis Date: 2012-04-09 Impact factor: 2.373
Authors: Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: Joel Philip Samuels; Aashna Sood; Jonathon R Campbell; Faiz Ahmad Khan; James Cameron Johnston Journal: Sci Rep Date: 2018-03-21 Impact factor: 4.379
Authors: Melanie Frank; Natalia Adamashvili; Nino Lomtadze; Eka Kokhreidze; Zaza Avaliani; Russell R Kempker; Henry M Blumberg Journal: Open Forum Infect Dis Date: 2019-03-29 Impact factor: 3.835
Authors: Muhammad Osman; Elizabeth P Harausz; Anthony J Garcia-Prats; H Simon Schaaf; Brittany K Moore; Robert M Hicks; Jay Achar; Farhana Amanullah; Pennan Barry; Mercedes Becerra; Domnica I Chiotan; Peter C Drobac; Jennifer Flood; Jennifer Furin; Medea Gegia; Petros Isaakidis; Andrei Mariandyshev; Iveta Ozere; N Sarita Shah; Alena Skrahina; Elena Yablokova; James A Seddon; Anneke C Hesseling Journal: Emerg Infect Dis Date: 2019-03 Impact factor: 6.883
Authors: Elizabeth P Harausz; Anthony J Garcia-Prats; Stephanie Law; H Simon Schaaf; Tamara Kredo; James A Seddon; Dick Menzies; Anna Turkova; Jay Achar; Farhana Amanullah; Pennan Barry; Mercedes Becerra; Edward D Chan; Pei Chun Chan; Domnica Ioana Chiotan; Aldo Crossa; Peter C Drobac; Lee Fairlie; Dennis Falzon; Jennifer Flood; Medea Gegia; Robert M Hicks; Petros Isaakidis; S M Kadri; Beate Kampmann; Shabir A Madhi; Else Marais; Andrei Mariandyshev; Ana Méndez-Echevarría; Brittany Kathryn Moore; Parpieva Nargiza; Iveta Ozere; Nesri Padayatchi; Saleem- Ur-Rehman; Natasha Rybak; Begoña Santiago-Garcia; N Sarita Shah; Sangeeta Sharma; Tae Sun Shim; Alena Skrahina; Antoni Soriano-Arandes; Martin van den Boom; Marieke J van der Werf; Tjip S van der Werf; Bhanu Williams; Elena Yablokova; Jae-Joon Yim; Jennifer Furin; Anneke C Hesseling Journal: PLoS Med Date: 2018-07-11 Impact factor: 11.069